Treatment Resistant Depression affects nearly 30% of all depressed individuals who fail to achieve remission after two or more antidepressant trials. Individuals suffering from Treatment Resistant Depression experience intense symptoms like depressed mood, loss of interest, feelings of worthlessness, disturbed sleep or appetite, poor concentration and recurrent thoughts of death or suicide. The ongoing research in novel treatment approaches like transcranial magnetic stimulation, electroconvulsive therapy, ketamine infusions and vagus nerve stimulation is fueling significant growth in the treatment resistant depression market. The global Treatment Resistant Depression Market is estimated to be valued at US$ 1220.12 Mn in 2024 and is expected to exhibit a CAGR of 22% over the forecast period 2024-2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The development of novel technologies like deep brain stimulation for treatment resistant depression presents a lucrative growth opportunity. Deep brain stimulation involves implantation of electrodes in specific areas of the brain linked with depression. Recent clinical trials have shown promising results of deep brain stimulation in reducing depression symptoms among non-responsive patients. With further research demonstrating its safety and effectiveness, deep brain stimulation could emerge as a mainstream treatment option for treatment resistant depression in the coming years. Its adoption would drive significant revenues in the global treatment resistant depression market during the forecast period.
Porter's Analysis
Threat of new entrants: The high capital requirements and risk associated with drug development creates significant barriers for new entrants in the treatment resistant depression market.
Bargaining power of buyers: The bargaining power of buyers is moderate as treatment resistant depression has few therapeutic alternatives. However, buyers can leverage over pricing to an extent.
Bargaining power of suppliers: The dependence on raw material suppliers is moderate giving suppliers some control over pricing. However, the availability of substitute materials curtails the pricing power of suppliers.
Threat of new substitutes: Potential substitutes with novel mechanisms of action can pose a threat to existing treatment options. Extensive research efforts are being made to develop new generation therapies.
Competitive rivalry: Intense research and development rivalry exists among key players to develop effective therapies and gain a competitive advantage.
SWOT Analysis
Strengths: Availability of new pipeline drugs and devices, growing awareness about mental health disorders.
Weaknesses: High relapse rates associated with treatment resistant depression, lack of biomarkers for personalized therapy.
Opportunities: Expanding healthcare infrastructure in emerging nations, collaboration opportunities between biopharma companies and research institutes.
Threats: Stringent regulatory approval process, side effects associated with antidepressant medications.
Key Takeaways
The global treatment resistant depression market scope is expected to witness high growth supported by rising prevalence, growing mental health funding and robust drug development pipelines. The market size is projected to reach over US$ 12 billion by 2030.
Regional analysis: North America currently dominates the global market and is expected to maintain its lead position during the forecast period. This can be attributed to the availability of advanced healthcare facilities, strong reimbursement framework and presence of major market players in the region. Asia Pacific is poised to witness fastest growth owing to growing healthcare spending, rising awareness and expanding patient pool in China and India.
Key players: Key players operating in the treatment resistant depression market are HempFlax, Cavac Biomateriaux, BaFa, Hemp Planet, Dunagro, American Hemp, Hempline, Hemp Inc, Ecofibre, GenCanna, Hemp Oil Canada, Hemp Poland, Plains Industrial Hemp Processing, Colorado Hemp Works, MH Medical Hemp, Hempco, Hempfield Farms, Hemp Tech, Tilray, Canopy Growth. These companies are focused on developing novel combination therapies, undertaking clinical trials and enhancing their global presence through collaborations and mergers & acquisitions.
Get more insights on this topic: https://www.trendingwebwire.com/treatment-resistant-depression-market-industry-insights-trends-treatment-resistant-depression-market/
Explore more information on this topic, Please visit: https://www.newsintv.com/health/crispr-and-cas-gene-a-revolutionary-gene-editing-technology/
